Loading...
XNASCTKB
Market cap878mUSD
Jan 13, Last price  
7.29USD
1D
-0.15%
1Q
36.13%
IPO
-61.96%
Name

Cytek Biosciences Inc

Chart & Performance

D1W1MN
XNAS:CTKB chart
P/E
P/S
4.87
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
193m
+17.67%
57,883,00092,839,000127,950,000164,036,000193,015,000
Net income
-12m
L
-16,827,00019,411,0004,417,0002,576,000-12,148,000
CFO
5m
P
-13,747,00015,156,0004,630,000-12,231,0005,281,000
Earnings
Jun 05, 2025

Profile

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
IPO date
Jul 23, 2021
Employees
699
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
193,015
17.67%
164,036
28.20%
Cost of revenue
220,860
165,840
Unusual Expense (Income)
NOPBT
(27,845)
(1,804)
NOPBT Margin
Operating Taxes
(3,561)
(1,224)
Tax Rate
NOPAT
(24,284)
(580)
Net income
(12,148)
-571.58%
2,576
-41.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
(44,151)
995
BB yield
3.58%
-0.07%
Debt
Debt current
3,009
3,511
Long-term debt
20,606
26,895
Deferred revenue
15,132
13,124
Other long-term liabilities
18,908
13,135
Net debt
(240,395)
(312,343)
Cash flow
Cash from operating activities
5,281
(12,231)
CAPEX
(4,648)
(9,868)
Cash from investing activities
(93,894)
(55,909)
Cash from financing activities
(41,812)
5,513
FCF
(39,264)
(36,212)
Balance
Cash
262,410
341,149
Long term investments
1,600
1,600
Excess cash
254,359
334,547
Stockholders' equity
(30,322)
502,135
Invested Capital
471,562
133,685
ROIC
ROCE
EV
Common stock shares outstanding
135,283
138,562
Price
9.12
-10.68%
10.21
-37.44%
Market cap
1,233,781
-12.79%
1,414,719
-35.19%
EV
993,386
1,622,103
EBITDA
(18,615)
3,855
EV/EBITDA
420.78
Interest
2,071
2,573
Interest/NOPBT